Drug intelligence / Profile preview

Jianpi Liqi Huashi decoction

Development stage: Unknown
Lead developer: Shanghai Pudong New Area Infectious Disease Hospital
Administration: Oral

Overview

Jianpi Liqi Huashi decoction is a traditional Chinese medicine (TCM) herbal formula developed by the Infectious Disease Hospital of Pudong New Area Shanghai. It is specifically designed to treat non-alcoholic steatohepatitis (NASH) by addressing the TCM patterns of spleen deficiency, Qi stagnation, and dampness accumulation. The decoction aims to improve clinical symptoms, reduce insulin resistance, and lower free fatty acid levels in patients with NASH. Its mechanism likely involves multi-target effects on lipid metabolism and insulin signaling pathways, though specific molecular targets for the whole mixture are not typically defined in Western pharmacological terms.

Brand names: Jianpi Liqi Huashi Decoction
Other names: Jianpi Liqi Huashi Tang

Beyond the preview

Go deeper on Jianpi Liqi Huashi decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jianpi Liqi Huashi decoction.

Explore the full profile